Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

BillionToOne Integrates Semaphore Solutions' Labbit LIMS into Precision Oncology Diagnostics Labs

NextEdge Admin

04 Sep 2024

2 min 23 sec

Semaphore Solutions, a leader in laboratory informatics, has expanded its partnership with BillionToOne, a next-generation molecular diagnostics company. BillionToOne is implementing Semaphore’s Labbit, a Laboratory Information Management System (LIMS), in its oncology labs to handle significant increases in sample throughput.

BillionToOne’s unique Quantitative Counting Templates™ (QCT™) technology enables single base-pair precision in DNA molecule counting, allowing the company to develop innovative molecular diagnostics tests. Previously, BillionToOne collaborated with Semaphore to successfully implement a different LIMS platform in its prenatal diagnostics labs, benefiting from Semaphore’s expertise in complex clinical genomics.

As BillionToOne prepared to launch oncology-focused products, they reevaluated their LIMS options and invited Semaphore to demonstrate Labbit's capabilities in an oncology setting. The laboratory leadership determined that Labbit’s compliance-ready, configurable, and scalable solution was the best fit for their high-complexity, high-throughput requirements.

John ten Bosch, SVP of Laboratory Operations at BillionToOne, stated, “We trusted Semaphore from our previous collaborations. When we saw Labbit in action, it was clear it was designed to address the challenges of other LIMS. We are confident it will support our current and future needs.”

Peter Smith, CEO of Semaphore, added, “Our collective experience in implementing LIMS informed Labbit’s design. It’s a flexible, cloud-based solution that improves efficiency and throughput while maintaining quality standards. We’re excited to partner with BillionToOne on this journey.”

Semaphore Solutions offers software solutions to leading life science and diagnostic organizations, while BillionToOne focuses on making molecular diagnostics more powerful and accessible.